Sanofi

Michael Podeschwa

Klaus Wirth

Oliver Plettenburg

Ulrich Werner

Stephanie Hachtel

Werngard Czechtizky

Gary Mccort

Olaf Ritzeler

Stefan Guessregen

Maria Mendez-Perez

John Weston

Matthias Loehn

Thomas Boehme

Kai Rossen

Aimo Kannt

Laurent Bialy

Hermut Wehlan

Volker Kraft

Petra Arndt

Kirsten Bjergarde

Nils Rackelmann

Heinz Goegelein

Yuri Ivashchenko

Marcus Korn

Patrice Bellevergue

Martin Will

Ana Villar Garea

Melissa Besenius

Maria Mendez Perez

Jens Riedel

The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.

Insulin conjugates

The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals

Growing community of inventors

Frankfurt am Main, Germany

Michael Podeschwa